Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind dose-ranging placebo-controlled study of PST2238 (rostafuroxin) in essential hypertension
2004-000415-26Phase 2Completed
- Sponsor
- Leadiant Biosciences
- Start
- Aug 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rostafuroxin in essential hypertension (5 arms), sponsored by Leadiant Biosciences. Primary endpoint: Office sitting systolic blood pressure. Started Aug 2004; status: completed.
02
Drugs
rostafuroxin
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2004-000415-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000415-26.